You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The company has begun establishing partnerships with medical centers for a large prospective study of its test for identifying aggressive tumors.
In PNAS this week: optical mapping study of multiple myeloma, role for miR-204 in form of retinal dystrophy, and more.
In Science this week: microRNA expression as marker for injury due to radiation exposure, and more.
Prolias accused PDI of breaching a joint venture agreement to validate, commercialize, and monetize Prolias' miRNA thyroid cancer test. PDI denied liability and said it would defend itself vigorously.
Cancer-ID is a newly created consortium tasked with validating blood-based biomarkers, such as CTC, cfDNA, and miRNA to bring liquid biopsies into the clinic.
In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.
The investment bank upgraded Rosetta's shares following the completion of the firm's purchase of PersonalizeDx earlier in the week.
With the support of an NIH grant, Nawgen aims to create assays covering all microRNAs in the human and mouse genomes.
A fourth paper from MIT's Robert Weinberg has been retracted, according to Retraction Watch.
The study indicates that miRNAs act as genomic noise dampeners, controlling variability in protein expression.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.